Anorex for the Significantly Overweight

For the millions of Americans who are significantly overweight (more than 30 lbs. of excess body weight and/or a BMI [body mass index] greater than 30) there is simply no longer any way to deny the genetic link to obesity. That's why ordinary diet pills and so-called "fat magnets" (if they work at all) so often fail to help the significantly overweight. The genetic link to obesity also means that repeated diet failure and chronic overweight is not your fault. Unless a weight-control compound addresses the genetic factor — and helps you overcome your genetic predisposition to obesity — your attempts at weight loss become no more than an exercise in futility (and a waste of time and money).

But now there's Anorex™ — the first weight-control compound designed to mitigate the profound effect that variations in the human genetic code have on the storage, use, and disposition of body fat.

Anorex™ is an extremely powerful anorectic agent and is not intended for use by the casual dieter who is merely attempting to shed five or ten "vanity" pounds. However, if substantial, excess body fat is adversely affecting your health and self-esteem, then it's time for you to discover Anorex™ — the first comprehensive weight-loss compound designed specifically to overcome your genetic predisposition.

Anorex™: The Result of an Extraordinary Collaboration

Anorex™ (or more correctly, its patent-protected core compound, Leptoprin™) is the result of an extraordinary collaborative effort between Dr. Daniel B. Mowrey, Director of Scientific Affairs, Klein-Becker usa, Provo, Utah, and Dr. Edward G. Fey, University of Massachusetts Medical Center, Worchester, Massachusetts. Though working independently, both doctors were keenly aware of the growing body of evidence linking obesity to certain genetic "markers." In September of 1998, Drs. Mowrey and Fey discovered each had access to compatible patents for variant methods of regulating obesity.

As they familiarized themselves with each others' work, it became clear that combining the patented formulations could overcome genetic anomalies responsible for significant overweight. In fact, a recent report ("The Human Obesity Gene Map: The 1999 Update") published in Obesity Research, the official journal for the North American Association for the Study of Obesity, disclosed, "The number of genes and other markers associated or linked with human obesity phenotypes continues to expand and now reaches well over 200" (Vol. 8 No. 1 Jan. 2000, p.105). For example, gene FABP2, located at 4q28-q31, impacts abdominal fat, body mass index, and fat percentage — while others are more specific, such as gene INS, located at 11p15.5, which influences waist-to-hip ratios in obese women (pp.99-100).